Impairment of the DNA damage response pathway as a potential contributor towards peripartum cardiomyopathy

Clicks: 1
ID: 323339
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal

Ranked #209 of 282 articles by views in European heart journal supplements : journal of the European Society of Cardiology

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 282 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Background and purpose Peripartum cardiomyopathy (PPCM) affects prior heart-healthy women in the peripartum phase and is characterized by systolic heart failure (HF). Data from a German/ Swedish PPCM cohort revealed a 16-fold increased cancer prevalence. Several patients who were diagnosed with both, PPCM and cancer, carried gene variants located on DNA-damage-response (DDR) genes and/or received anthracycline based chemotherapies prior to their PPCM diagnosis. Here, we investigated juvenile anthracycline treatment prior to pregnancy as well as the effect of DDR impairment during the peripartum phase using mice heterozygous for Ataxia-Telangiectasia-Mutated (ATM), and determined the frequency of ATM gene variants and plasma levels of ATM-targeting miRNAs in PPCM patients. Methods and results Female C57BL/6N mice who received juvenile doxorubicin (DOX, 4x4mg/kgBW) treatment prior to pregnancy showed high mortality in the late peripartum phase. DOX-treated mice who survived two pregnancies and nursing periods exhibited reduced cardiac function compared to untreated (wildtype) WT mice (ctrl). RNAseq analysis of LV tissue from ctrl postpartum (PP) mice had shown peripartum induced upregulation of several DDR related transcripts compared with nulli-pari (NP) mice. This upregulation did not occur among PP mice who received juvenile DOX treatment. Whole exome sequencing in 80 PPCM patients from the German PPCM registry identified 7 carriers of heterozygous ATM gene variants classified as variants of uncertain significance (VUS, n=6) or pathogenic (P, n=1). MiRNA-screening by using human TaqMan Array Cards identified elevated plasma levels of 5 miRNAs potentially targeting ATM in PPCM patients compared to heart-healthy PP-matched women. Overexpression of miRNA precursors of two of these miRNAs, miR-18a-5p and miR-18b-5p, resulted in the reduction of ATM protein levels in HL1 cardiomyocytes. As proof-of-concept, we used a heterozygous ATM (ATM+/-) mouse model carrying a targeted mutation (Atmins5790neo) leading to a reduced protein expression. After 4 pregnancies and nursing periods (4xPP) ATM+/- mice showed systolic dysfunction and cardiac hypertrophy in contrast to WT 4xPP, ATM+/- NP and WT NP mice (FAC%: WT: 49±5 vs ATM+/-: 37±9; P<0.001). Moreover, mice with PPCM due to cardiac STAT3 deficiency (aMHCxCretg/+;STAT3flox/flox, CKO) and additional ATM heterozygosity showed an aggravated heart failure phenotype compared with CKO PP mice (FS%: CKO: 23.8±3 vs CKO/ATM+/-: 17.3±3.3; P<0.0005) associated with an induction of cell-cycle regulators p21 and Caspase 3. In conclusion, our data suggests that the DDR pathway may be an important link between cancer and PPCM. Latent side effects of DOX therapy by DDR suppression as well as detrimental effects of DDR related gene variants are potential shared mechanisms. In line, reduced ATM expression induces cardiac dysfunction and hypertrophy in the ATM+/-PP mice and aggravates HF in CKO;ATM+/- PP mice.
Reference Key
openalex_W7172266939 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors T Gausepohl, S Pietzsch, B Auber, M Kasten, T J Pfeffer, B Pabst, S Erschow, J Viereck, T Thum, J Bauersachs, D Hilfiker-Kleiner, M Ricke-Hoch
Journal European heart journal supplements : journal of the European Society of Cardiology
Year 2026
DOI
10.1093/eurheartjsupp/suag097.213
URL
https://doi.org/10.1093/eurheartjsupp/suag097.213
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.